Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

New Perspectives in Pediatric Nonalcoholic Fatty Liver Disease: Epidemiology, Genetics, Diagnosis, and Natural History

  • Ko, Jae Sung (Department of Pediatrics, Seoul National University College of Medicine)
  • Received : 2019.10.02
  • Accepted : 2019.10.29
  • Published : 2019.11.15
Download PDF
⟨ Previous Next ⟩

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in children. The global prevalence of pediatric NAFLD from general populations is 7.6%. In obese children, the prevalence is higher in Asia. NAFLD has a strong heritable component based on ethnic difference in the prevalence and clustering within families. Genetic polymorphisms of patatin-like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6 superfamily member 2, and glucokinase regulatory protein (GCKR) are associated with the risk of NAFLD in children. Variants of PNPLA3 and GCKR are more common in Asians. Alterations of the gut microbiome might contribute to the pathogenesis of NAFLD. High fructose intake increases the risk of NAFLD. Liver fibrosis is a poor prognostic factor for disease progression to cirrhosis. Magnetic resonance spectroscopy and magnetic resonance proton density fat fraction are more accurate for steatosis quantification than ultrasound. Noninvasive imaging methods to assess liver fibrosis, such as transient elastography, shear-wave elastography, and magnetic resonance elastography are useful in predicting advanced fibrosis, but they need further validation. Longitudinal follow-up studies into adulthood are needed to better understand the natural history of pediatric NAFLD.

Keywords

References

  1. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21. https://doi.org/10.1053/j.gastro.2005.04.014
  2. Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One 2015;10:e0140908. https://doi.org/10.1371/journal.pone.0140908
  3. Kim JW, Lee KJ, Yang HR, Chang JY, Moon JS, Khang YH, Ko JS Prevalence and risk factors of elevated alanine aminotransferase among Korean adolescents: 2001-2014. BMC Public Health 2018;18:617. https://doi.org/10.1186/s12889-018-5548-9
  4. Cho YH, Kim JW, Shim JO, Yang HR, Chang JY, Moon JS, et al. Association between vitamin D deficiency and suspected nonalcoholic fatty liver disease in an adolescent population. Pediatr Gastroenterol Hepatol Nutr 2019;22:233-41. https://doi.org/10.5223/pghn.2019.22.3.233
  5. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388-93. https://doi.org/10.1542/peds.2006-1212
  6. Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009;49:791-801. https://doi.org/10.1002/hep.22726
  7. Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, Schork NJ, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009;136:1585-92. https://doi.org/10.1053/j.gastro.2009.01.050
  8. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-5. https://doi.org/10.1038/ng.257
  9. Koo BK, Joo SK, Kim D, Bae JM, Park JH, Kim JH, et al. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2018;33:1277-85. https://doi.org/10.1111/jgh.14056
  10. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-17. https://doi.org/10.1002/hep.23622
  11. Speliotes EK, Butler JL, Palmer CD, Voight BF, ; GIANT Consortium; MIGen Consortium; NASH CRN, Hirschhorn JN. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010;52:904-12. https://doi.org/10.1002/hep.23768
  12. Wei JL, Leung JC, Loong TC, Wong GL, Yeung DK, Chan RS, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol 2015;110:1306-14; quiz 1315. https://doi.org/10.1038/ajg.2015.235
  13. Romeo S, Sentinelli F, Cambuli VM, Incani M, Congiu T, Matta V, et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 2010;53:335-8. https://doi.org/10.1016/j.jhep.2010.02.034
  14. Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH. A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. J Pediatr 2011;158:740-4. https://doi.org/10.1016/j.jpeds.2010.11.016
  15. Larrieta-Carrasco E, Leon-Mimila P, Villarreal-Molina T, Villamil-Ramirez H, Romero-Hidalgo S, Jacobo-Albavera L, et al. Association of the I148M/PNPLA3 variant with elevated alanine transaminase levels in normal-weight and overweight/obese Mexican children. Gene 2013;520:185-8. https://doi.org/10.1016/j.gene.2013.03.038
  16. Viitasalo A, Pihlajamaki J, Lindi V, Atalay M, Kaminska D, Joro R, et al. Associations of I148M variant in PNPLA3 gene with plasma ALT levels during 2-year follow-up in normal weight and overweight children: the PANIC Study. Pediatr Obes 2015;10:84-90. https://doi.org/10.1111/ijpo.234
  17. Mangge H, Baumgartner BG, Zelzer S, Pruller F, Schnedl WJ, Reininghaus EZ, et al. Patatin-like phospholipase 3 (rs738409) gene polymorphism is associated with increased liver enzymes in obese adolescents and metabolic syndrome in all ages. Aliment Pharmacol Ther 2015;42:99-105. https://doi.org/10.1111/apt.13232
  18. Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjaerg-Hansen A, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014;46:352-6. https://doi.org/10.1038/ng.2901
  19. Goffredo M, Caprio S, Feldstein AE, D'Adamo E, Shaw MM, Pierpont B, et al. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study. Hepatology 2016;63:117-25. https://doi.org/10.1002/hep.28283
  20. Grandone A, Cozzolino D, Marzuillo P, Cirillo G, Di Sessa A, Ruggiero L, et al. TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children. Pediatr Obes 2016;11:115-9. https://doi.org/10.1111/ijpo.12032
  21. Zain SM, Mohamed Z, Mohamed R. Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis. J Gastroenterol Hepatol 2015;30:21-7. https://doi.org/10.1111/jgh.12714
  22. Goyal NP, Schwimmer JB. The genetics of pediatric nonalcoholic fatty liver disease. Clin Liver Dis 2018;22:59-71. https://doi.org/10.1016/j.cld.2017.08.002
  23. Lin YC, Chang PF, Chang MH, Ni YH. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr 2014;99:869-74. https://doi.org/10.3945/ajcn.113.079749
  24. Di Sessa A, Umano GR, Cirillo G, Del Prete A, Iacomino R, Marzuillo P, et al. The membrane-bound O-Acyltransferase7 rs641738 variant in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2018;67:69-74. https://doi.org/10.1097/MPG.0000000000001979
  25. Palmer ND, Musani SK, Yerges-Armstrong LM, Feitosa MF, Bielak LF, Hernaez R, et al. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent. Hepatology 2013;58:966-75. https://doi.org/10.1002/hep.26440
  26. Trico D, Caprio S, Rosaria Umano G, Pierpont B, Nouws J, Galderisi A, et al. Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in obese adolescents: findings from a multiethnic cohort. Hepatology 2018;68:1376-90. https://doi.org/10.1002/hep.30035
  27. Zusi C, Mantovani A, Olivieri F, Morandi A, Corradi M, Miraglia Del Giudice E, et al. Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents. Dig Liver Dis 2019. doi: 10.1016/j.dld.2019.05.029. [Epub ahead of print].
  28. Stender S, Kozlitina J, Nordestgaard BG, Tybjaerg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 2017;49:842-7. https://doi.org/10.1038/ng.3855
  29. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013;57:601-9. https://doi.org/10.1002/hep.26093
  30. Del Chierico F, Nobili V, Vernocchi P, Russo A, De Stefanis C, Gnani D, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology 2017;65:451-64. https://doi.org/10.1002/hep.28572
  31. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 2017;25:1054-62.e5. https://doi.org/10.1016/j.cmet.2017.04.001
  32. Schwimmer JB, Johnson JS, Angeles JE, Behling C, Belt PH, Borecki I, et al. Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Gastroenterology 2019;157:1109-22. https://doi.org/10.1053/j.gastro.2019.06.028
  33. O'Sullivan TA, Oddy WH, Bremner AP, Sherriff JL, Ayonrinde OT, Olynyk JK, et al. Lower fructose intake may help protect against development of nonalcoholic fatty liver in adolescents with obesity. J Pediatr Gastroenterol Nutr 2014;58:624-31. https://doi.org/10.1097/MPG.0000000000000267
  34. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, et al. Consuming fructosesweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009;119:1322-34. https://doi.org/10.1172/JCI37385
  35. Malik VS, Hu FB. Fructose and cardiometabolic health: what the evidence from sugar-sweetened beverages tells us. J Am Coll Cardiol 2015;66:1615-24. https://doi.org/10.1016/j.jacc.2015.08.025
  36. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014;146:726-35. https://doi.org/10.1053/j.gastro.2013.11.049
  37. Nobili V, Alisi A, Valenti L, Miele L, Feldstein AE, Alkhouri N. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol 2019;16:517-30. https://doi.org/10.1038/s41575-019-0169-z
  38. Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008;118:277-83. https://doi.org/10.1161/CIRCULATIONAHA.107.739920
  39. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-51. https://doi.org/10.1172/JCI23621
  40. Braun HA, Faasse SA, Vos MB. Advances in pediatric fatty liver disease: pathogenesis, diagnosis, and treatment. Gastroenterol Clin North Am 2018;47:949-68. https://doi.org/10.1016/j.gtc.2018.07.016
  41. Jin R, Willment A, Patel SS, Sun X, Song M, Mannery YO, et al. Fructose induced endotoxemia in pediatric nonalcoholic Fatty liver disease. Int J Hepatol 2014;2014:560620.
  42. Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017;64:319-34. https://doi.org/10.1097/MPG.0000000000001482
  43. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21. https://doi.org/10.1002/hep.20701
  44. Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42:641-9. https://doi.org/10.1002/hep.20842
  45. Ko JS, Yoon JM, Yang HR, Myung JK, Kim H, Kang GH, et al. Clinical and histological features of nonalcoholic fatty liver disease in children. Dig Dis Sci 2009;54:2225-30. https://doi.org/10.1007/s10620-009-0949-3
  46. Carter-Kent C, Brunt EM, Yerian LM, Alkhouri N, Angulo P, Kohli R, et al. Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2011;52:190-7. https://doi.org/10.1097/MPG.0b013e3181fb47d3
  47. Mansoor S, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, et al. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Dig Dis Sci 2015;60:1440-7. https://doi.org/10.1007/s10620-014-3494-7
  48. Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006;44:458-65. https://doi.org/10.1002/hep.21262
  49. Manco M, Marcellini M, Devito R, Comparcola D, Sartorelli MR, Nobili V. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes (Lond) 2008;32:381-7. https://doi.org/10.1038/sj.ijo.0803711
  50. Shannon A, Alkhouri N, Carter-Kent C, Monti L, Devito R, Lopez R, et al. Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. J Pediatr Gastroenterol Nutr 2011;53:190-5. https://doi.org/10.1097/MPG.0b013e31821b4b61
  51. Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013;58:1930-40. https://doi.org/10.1002/hep.26455
  52. Middleton MS, Van Natta ML, Heba ER, Alazraki A, Trout AT, Masand P, et al.; NASH Clinical Research Network. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology 2018;67:858-72. https://doi.org/10.1002/hep.29596
  53. Yang HR, Kim HR, Kim MJ, Ko JS, Seo JK. Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. World J Gastroenterol 2012;18:1525-30. https://doi.org/10.3748/wjg.v18.i13.1525
  54. Mansoor S, Collyer E, Alkhouri N. A comprehensive review of noninvasive liver fibrosis tests in pediatric nonalcoholic fatty liver disease. Curr Gastroenterol Rep 2015;17:23. https://doi.org/10.1007/s11894-015-0447-z
  55. Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008;48:442-8. https://doi.org/10.1002/hep.22376
  56. Lee CK, Perez-Atayde AR, Mitchell PD, Raza R, Afdhal NH, Jonas MM. Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience. J Pediatr 2013;163:1058-64.e2. https://doi.org/10.1016/j.jpeds.2013.04.044
  57. Garcovich M, Veraldi S, Di Stasio E, Zocco MA, Monti L, Toma P, et al. Liver stiffness in pediatric patients with fatty liver disease: diagnostic accuracy and reproducibility of shear-wave elastography. Radiology 2017;283:820-7. https://doi.org/10.1148/radiol.2016161002
  58. Etchell E, Juge L, Hatt A, Sinkus R, Bilston LE. Liver stiffness values are lower in pediatric subjects than in adults and increase with age: a multifrequency MR elastography study. Radiology 2017;283:222-30. https://doi.org/10.1148/radiol.2016160252
  59. Schwimmer JB, Behling C, Angeles JE, Paiz M, Durelle J, Africa J, et al. Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease. Hepatology 2017;66:1474-85. https://doi.org/10.1002/hep.29241
  60. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A metaanalysis. Hepatology 2017;66:1486-501. https://doi.org/10.1002/hep.29302
  61. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-97.e10. https://doi.org/10.1053/j.gastro.2015.04.043
  62. Holterman AX, Guzman G, Fantuzzi G, Wang H, Aigner K, Browne A, et al. Nonalcoholic fatty liver disease in severely obese adolescent and adult patients. Obesity (Silver Spring) 2013;21:591-7. https://doi.org/10.1002/oby.20174
  63. A-kader H, Henderson J, Vanhoesen K, Ghishan F, Bhattacharyya A. Nonalcoholic fatty liver disease in children: a single center experience. Clin Gastroenterol Hepatol 2008;6:799-802. https://doi.org/10.1016/j.cgh.2008.03.001
  64. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-68. https://doi.org/10.1001/jama.2011.520
  65. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008;48:119-28. https://doi.org/10.1002/hep.22336
  66. Cioffi CE, Welsh JA, Cleeton RL, Caltharp SA, Romero R, Wulkan ML, et al. Natural history of NAFLD diagnosed in childhood: a single-center study. Children (Basel) 2017;4:E34.
  67. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009;58:1538-44. https://doi.org/10.1136/gut.2008.171280
  68. Goyal NP, Schwimmer JB. The Progression and natural history of pediatric nonalcoholic fatty liver disease. Clin Liver Dis 2016;20:325-38. https://doi.org/10.1016/j.cld.2015.10.003

Cited by

  1. Noninvasive diagnostic tools for pediatric NAFLD: where are we now? vol.14, pp.11, 2019, https://doi.org/10.1080/17474124.2020.1801413
  2. Predictors of liver fat among children and adolescents from five different ethnic groups vol.7, pp.1, 2019, https://doi.org/10.1002/osp4.459
  3. Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications vol.18, pp.2, 2021, https://doi.org/10.1038/s41569-020-0433-5
  4. Role of microbiota and related metabolites in gastrointestinal tract barrier function in NAFLD vol.9, pp.3, 2021, https://doi.org/10.1080/21688370.2021.1879719
  5. Relationship between Quantitative Sonographic Measurements and Serum Biochemical Parameters in Childhood Obesity vol.24, pp.5, 2019, https://doi.org/10.5223/pghn.2021.24.5.470
  6. PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling vol.12, pp.1, 2021, https://doi.org/10.1038/s41467-021-23285-8